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Cancer-associated noncoding 
mutations affect RNA 
G-quadruplex-mediated regulation 
of gene expression
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Daniel U. Christ1,2, Tracy M. Bryan  3 & Marcel E. Dinger  1,2
Cancer is a multifactorial disease driven by a combination of genetic and environmental factors. Many 
cancer driver mutations have been characterised in protein-coding regions of the genome. However, 
mutations in noncoding regions associated with cancer have been less investigated. G-quadruplex (G4) 
nucleic acids are four-stranded secondary structures formed in guanine-rich sequences and prevalent 
in the regulatory regions. In this study, we used published whole cancer genome sequence data to 
find mutations in cancer patients that overlap potential RNA G4-forming sequences in 5′ UTRs. Using 
RNAfold, we assessed the effect of these mutations on the thermodynamic stability of predicted 
RNA G4s in the context of full-length 5′ UTRs. Of the 217 identified mutations, we found that 33 are 
predicted to destabilise and 21 predicted to stabilise potential RNA G4s. We experimentally validated 
the effect of destabilising mutations in the 5′ UTRs of BCL2 and CXCL14 and one stabilising mutation 
in the 5′ UTR of TAOK2. These mutations resulted in an increase or a decrease in translation of these 
mRNAs, respectively. These findings suggest that mutations that modulate the G4 stability in the 
noncoding regions could act as cancer driver mutations, which present an opportunity for early cancer 
diagnosis using individual sequencing information.
Substantial efforts have been made to characterise the cancer genome. The advent of next generation sequencing 
has enabled affordable and rapid large-scale sequencing of cancer genomes. The Cancer Genome Atlas (TCGA)1 
and the International Cancer Genome Consortium2 are examples of large-scale cancer genomics projects that 
aim to catalogue cancer-associated mutations. One of the main goals of these projects is to differentiate cancer 
driver mutations, which contribute to cancer development, from non-functional passenger mutations and ulti-
mately improve our understanding of how different types of cancers develop3. As a result of extensive efforts that 
have been directed towards detecting and characterising driver mutations in protein-coding regions, knowledge 
about abnormal proteins encoded by mutated cancer genes has grown substantially in recent years, such that 
new cancer therapeutics have been developed to target these anomalous proteins. Imatinib is an example of this 
type of therapeutic that inhibits the protein encoded by ABL, which is mutated in chronic myeloid leukaemia4. 
Noncoding somatic mutations, on the other hand, have not been examined as extensively as coding variations. 
Considering that less than 2% of the human genome encodes protein and that important regulatory regions 
including promoters and 5′ and 3′ untranslated regions (UTR) of mRNAs are located in the noncoding regions5, 
effective functional studies of mutations in the noncoding regions would provide a better understanding of cancer 
biology and development. Indeed, several studies have indicated that noncoding somatic mutations can alter gene 
expression in cancer6–8, prompting the hypothesis that these mutations affect regulatory motifs.
Guanine (G)-rich DNA and RNA sequences can fold into non-canonical secondary structures called 
G-quadruplexes (G4s). The building block of a G4 is called a G-tetrad, which consists of four guanines in a square 
planar arrangement. Each guanine is connected to the two adjacent guanines by hydrogen bonds at the Watson 
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Crick and Hoogsteen edges. The G4 structure is formed by at least two stacked G-tetrads. A cation positioned at 
the center of each tetrad or between them further stabilises the G4 structure. Nucleotides that do not contribute 
to the G-tetrads form the loops9. Intramolecular G4 is assembled from guanines within one nucleic acid strand, 
whereas separate nucleic acid strands can form an intermolecular G4. Intramolecular DNA G4s can adopt various 
topologies10, whereas intramolecular RNA G4s predominantly fold into the parallel propeller topology11. Several 
different G4 structures have been studied in vitro. The results from these studies have enabled the development 
of algorithms that predict potential G4-forming sequences in the genome12–14. Using these algorithms, compu-
tational studies have demonstrated that G4s are significantly enriched and conserved in regulatory elements, 
such as promoters and UTRs of mRNAs15. This observation suggests that G4s may have regulatory roles and be 
involved in biological processes.
A number of studies have demonstrated that G4s located in the 5′ UTRs modulate translation activity. 
Although it has been shown that G4 can augment translation16, most G4s that have been characterised to date 
act as repressors in the cap-dependent translation regulation of mRNA translation17–20, especially in case of 
proto-oncogenes, such as NRAS21. Given accumulating in vitro results that demonstrate 5′ UTR G4s have regu-
latory functions and the increasing evidence that show G4 structures exist in vivo22, 23 and a number are altered 
in cancer tissues24, we hypothesized that mutations in cancer patients alter the stability of 5′ UTR G4s and conse-
quently affect their regulatory function.
Here, we present an approach that permitted us to identify somatic mutations in cancer that change the sta-
bility of 5′ UTR G4s. We have experimentally validated the effect of some of these mutations and showed that 
they can either destabilise RNA G4 structures or stabilise them. Furthermore, the mutations result in altered gene 
expression. Overall, our data suggest that mutations in regulatory elements such as 5′ UTR that alter G4s stability 
could act as cancer driver mutations.
Results
Somatic mutations in cancer patients change the thermodynamic stability of RNA G4s in the 5′ 
UTR. Previous studies have demonstrated that RNA G4s act as regulatory motifs in the 5′ UTR of mRNAs. To 
determine the possible effects of mutations in cancer patients on the stability of G4s in this region, the procedure 
illustrated in Fig. 1 was followed. A dataset of potential G4-forming sequences in the human genome was con-
structed. Quadparser algorithm13, which searches for the sequence pattern G3+N1–7G3+N1–7G3+N1–7G3+ across 
the genome, was employed to identify potential G4s. In this pattern, G refers to guanine and N can be any base 
including guanine. Concurrently, three publicly available databases, TCGA1, ICGC2 and Alexandrov et al.25, were 
used to obtain somatic mutation data in patients with different types of cancers. Comparing these two datasets, 
217 overlaps were found between somatic mutations from cancer patients and potential G4-forming sequences in 
the 5′ UTRs (Supplementary Dataset). Considering that putative G4 sequences might fold into other secondary 
structures instead of G4 structures, it is possible that overlapping mutations do not affect RNA G4 structural 
stability. To address this possibility, a further screening step was performed that investigated the effect of each 
mutation on the predicted RNA G4 stability using RNAfold software26. In addition to the G4 sequence pattern 
(G2–7N1–15G2–7N1–15G2–7N1–15G2–7), RNAfold takes account of thermodynamic parameters and is therefore a more 
stringent method to predict G4 structures. To simulate a more biologically relevant condition, the effect of each 
mutation was examined in the context of the entire 5′ UTR.
We found 33 RNA G4 destabilising mutations among 217 overlaps between somatic mutations and predicted 
5′ UTR G4s listed in the Supplementary Table 2. Based on the RNAfold predictions, these mutations remove one 
or more of the G-tetrads, increase the loop length or shift the RNA G4 position. A majority of them are transitions 
from guanine to adenine (Fig. 2A). On the other hand, 21 of the overlaps were found to be RNA G4 stabilising 
mutations (Supplementary Table 3). As predicted by RNAfold, in general, these mutations either increase the 
Figure 1. Flowchart illustrating the procedure for identifying mutations that change predicted RNA G4 
stability in the 5′ UTRs of genes mutated in cancer.
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number of G-tetrads or shorten a loop length. Most of them are transversions from uracil to guanine (Fig. 2B). 
To evaluate the accuracy of the in silico results, one stabilising mutation in the 5′ UTR of TAOK2 (TAO Kinase 2), 
one destabilising mutation in the 5′ UTR of BCL2 (B-cell lymphoma 2) and two adjacent destabilising mutations 
in the 5′ UTR of CXCL14 (C-X-C motif ligand 14) were selected for experimental validation.
A point mutation destabilises the RNA G4 in the 5′ UTR of BCL2. It has been well demonstrated that 
the over-expression of BCL2 proto-oncogene contributes to the resistance of cancer cells to apoptosis27. Our bio-
informatics analysis identified a guanine to adenine point mutation in a patient with malignant lymphoma, which 
was predicted to destabilise the RNA G4 in the 5′ UTR of BCL2 (Supplementary Table 2). It has been previously 
shown that the BCL2 RNA G4 is very stable near physiological ionic and pH conditions and acts as a translational 
repressor in the 5′ UTR of the BCL2 proto-oncogene28. To assess to what extent the mutation can destabilise the 
BCL2 RNA G4, in silico, in vitro and in cellulo evaluations were conducted. RNAfold and QGRS-Mapper14 both 
predict the same RNA G4 with three G-tetrads for the wild-type sequence. However, RNAfold does not predict 
any G4 structure for the mutated BCL2 G4 sequence, whereas QGRS-Mapper predicts a G4 structure with two 
G-tetrads (Fig. 3A; Supplementary Table 4).
CD spectroscopy is a well-established method to characterise the structure of G4s. A negative peak near 
240 nm and a positive peak near 260 nm in the CD spectrum are characteristics of a parallel G429. CD spectra of 
wild-type and mutated BCL2 RNA G4 oligos were recorded in near physiological pH and potassium concentra-
tion. Both wild-type and mutant oligos can fold into a parallel G4 conformation (Fig. 3B). It is noteworthy that 
the CD spectrum of the mutated RNA G4 oligo is in accordance with the QGRS-Mapper result, which predicts 
an RNA G4 containing two G-tetrads for this oligo. CD melting at 260 nm was performed to compare the stabil-
ity of wild-type and mutated BCL2 RNA G4 oligos (Fig. 3C). Compared to the wild-type RNA G4 oligo, a 14 °C 
decrease in the Tm value of mutated oligo was observed (Table 1).
Luciferase reporter assays were performed to evaluate the impact of the identified BCL2 point mutation on 
this RNA G4’s function in vitro. Three constructs were generated by cloning full-length wild-type, G4-mutant and 
G4-deleted 5′ UTRs of BCL2 immediately downstream of a T7 promoter and upstream of the firefly luciferase 
gene (Fig. 3A). For each construct, 5′-capped RNA transcripts were generated in vitro using T7 RNA polymerase. 
Equal transcript amounts from each construct were subjected to in vitro translation using nuclease-treated rabbit 
reticulocyte lysate and translation efficiency was determined by measuring firefly luciferase catalytic activity. The 
deletion of RNA G4 sequence from the 5′ UTR resulted in the highest relative translation efficiency (Fig. 3D), 
which supports the notion that the RNA G4 in the 5′ UTR of BCL2 act as a translational repressor. Compared 
to the wild-type, a guanine to adenine point mutation in the 5′ UTR of BCL2 resulted in a significant increase in 
translation efficiency (P < 0.0001), which is consistent with destabilisation of the RNA G4 structure.
Although in silico analysis using RNAfold and in vitro luciferase reporter assay have been performed in the 
context of the entire 5′ UTR of BCL2, we repeated the biophysical studies using 62-mer oligos of the wild-type and 
mutated BCL2 RNA G4 that had 20 extra nucleotides from each side (Supplementary Table 1) to investigate if the 
flanking sequences can affect the G4 structure and stability. As recorded for the 22-mer wild-type and mutated 
oligos, CD spectroscopy showed a negative peak near 240 nm and a positive peak near 260 nm for both 62-mer 
wild-type and mutated oligos (Fig. 4A). CD melting of 62-mer oligos showed that the Tm value of the mutated 
Figure 2. Pie chart demonstrating the frequency of different type of mutations in each of the RNA G4 (A) 
destabilising and (B) stabilising mutation groups.
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oligo is 16.5 °C less than the wild-type oligo (Fig. 4B and Table 1). These observations suggest that even in the 
presence of the flanking sequences, wild-type and mutated BCL2 RNA G4 oligos fold into G4 structures, however, 
the mutated G4 is less stable.
To investigate the effect of the mutation on the translation level in cellulo and to validate the in vitro reporter 
assay results, we performed dual luciferase assay. For this purpose, the T7 promoter was replaced by CMV 
Figure 3. A point mutation in the 5′ UTR of BCL2 destabilises the RNA G4 and affects its regulatory function. 
(A) Schematic representation of three different mRNAs of firefly luciferase reporter constructs. Wild-type 
construct contains full-length 5′ UTR of BCL2. In the G4-mutated construct, one of the guanines is replaced by 
adenine. To make the G4-deleted construct, 22 nucleotides that form the G4 were deleted. Schematic drawing 
of wild-type and mutated G4s are proposed based on RNAfold and QGRS-mapper predictions and in vitro 
results. (B) CD spectra of BCL2 wild-type and mutated RNA G4 oligos in KCl. (C) CD melting curves of BCL2 
wild-type and mutated RNA G4 oligos at 260 nm. (D) Relative in vitro translation efficiency of the wild-type, 
G4-mutated and G4-deleted constructs as judged by measuring firefly luciferase enzymatic activity. Data 
were analysed using one-way-ANOVA (n ≥ 3, error bars represent the SEM, asterisks (*) indicate significance 
calculated by the Tukey multiple comparisons test, ns indicates non-significant).
RNA G4 oligos Tm (°C)a
BCL2
wt 78 ± 2.1
mut 64 ± 0.2
Long BCL2b
wt 74.5 ± 3.5
mut 58 ± 2
CXCL14
wt >90c
mut 73 ± 0.5
TAOK2
wt 68 ± 0.5
mut 75 ± 1
Table 1. Melting temperatures of RNA G4 oligos annealed in 100 mM KCl, 20 mM Tris-HCl, pH 7.5. aTm values 
are expressed as mean ± SD (n ≥ 2). bLong BCL2 consists of 22 nucleotides predicted to form the RNA G4 and 
20 extra nucleotides from each side. cCXCL14 wt RNA G4 oligo could not be completely melted even at 95 °C.
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promoter in the wild-type and G4-mutant constructs, which have been described earlier, and each of these con-
structs co-transfected into MCF-7 cells together with pRL-TK as a normalizing vector and luciferase activity 
was measured. We observed ~75% higher translation level from G4-mutant construct (Fig. 4C) which is almost 
the same as in vitro translation results (Fig. 3D). In order to confirm that the observed difference in the gene 
expression level is due to the post-transcriptional regulation by the destabilised G4 in the 5′ UTR rather than 
the transcriptional regulation, we performed RT-qPCR on the total RNA extracted from the same samples used 
for the dual luciferase assay. As shown in Fig. 4C, there is no significant difference between the wild-type and 
G4-mutant constructs at the mRNA expression level which verifies post-transcriptional regulation is responsible 
for the difference observed in the protein expression level.
Two adjacent mutations destabilise the RNA G4 in the 5′ UTR of CXCL14. The length of loops 
within an RNA G4 are inversely proportional to its stability30. We identified several mutations predicted to desta-
bilise RNA G4s by lengthening one of the loops (Supplementary Table 2). These mutations are located in a G-rich 
region, which more than four G-runs exist. Theoretically, just four of the G-runs with shorter loops contribute to 
the RNA G4 structure. When a destabilising mutation disrupts one of the G-runs involved in the G4 structure, the 
fifth G-run, which is a few nucleotides away from the destabilised G4, contributes to the G4 formation and one 
of the loops lengthens. As an example, two adjacent guanine to adenine mutations in a patient with melanoma 
can disrupt one of the five G-runs in the 5′ UTR of CXCL14 and destabilise the predicted RNA G4. CXCL14 is 
a chemokine, which mainly contributes to the regulation of immune cell migration31. RNAfold predicts a total 
disruption of the RNA G4 caused by these mutations in the context of a full-length 5′ UTR. However, RNALfold, 
which scans for locally stable secondary structures, and QGRS-Mapper both predict an RNA G4 with a longer 
loop and less stability (Fig. 5A; Supplementary Table 4).
To investigate whether predicted wild-type and mutated CXCL14 RNA G4s could fold into G4 structures 
in vitro, CD spectra of these oligos were recorded in near physiological pH and potassium concentration. The 
wild-type oligo was designed to consist of five G-runs, whereas in the G4-mutated oligo, two of the guanines 
were replaced by adenines in the second G-run (Fig. 5A; Supplementary Tables 1 and 4). The negative peak near 
240 nm and the positive peak near 260 nm in the CD spectra of wild-type and G4-mutated oligos indicate that 
both oligos form parallel G4 structures (Fig. 5B). As the CXCL14 RNA G4 has not been characterized in vitro 
before, to exclude the possibility of a false positive G4 signature, the CD spectroscopy was repeated while the 
potassium in the buffer was replaced by lithium. It has been shown previously that lithium does not support G4 
structure formation as strongly as potassium. As shown in Supplementary Figure 1, a significant difference is 
observed between the CD spectrum of wild-type CXCL14 RNA G4 in the presence of 100 mM of lithium com-
pared with the same G4 in 100 mM of potassium. While CD spectroscopy results indicate both wild-type and 
mutated oligos can fold into parallel G4 structures, CD melting curves and Tm values of these two oligos show that 
the mutated oligo is less stable than the wild-type (Fig. 5C; Table 1). This might be because the mutations change 
the arrangement of G-runs and lengthen one of the loops, as predicted by RNALfold and QGRS-mapper (Fig. 5A; 
Supplementary Table 4).
To investigate the effect of these two mutations on the function of the CXCL14 RNA G4 in vitro, three differ-
ent luciferase reporter constructs were generated (Fig. 5A) as described earlier for BCL2. Quantitation of lucif-
erase catalytic activity showed that the translational efficiency for the G4-mutated construct is higher than the 
wild-type construct and lower than the G4-deleted construct (P < 0.0001), which supports an effect of the desta-
bilised RNA G4 in de-repressing translation (Fig. 5D).
Figure 4. Further characterization of the RNA G4 destabilising mutation in the 5′ UTR of BCL2 (A) CD 
spectra of wild-type and mutated BCL2 oligomer which consist of 22 nucleotides predicted to form the G4 and 
20 flanking nucleotides in KCl. (B) CD melting curves of wild-type and mutated BCL2 oligomer at 260 nm. 
(C) Gene expression level of wild-type and G4-mutated construct at the protein level as determined by dual 
luciferase assay and the mRNA level as determined by RT-qPCR. Data were analysed using multiple t-test 
(n ≥ 2, error bars represent the SEM, asterisks (*) indicate significance and ns indicates non-significant).
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 708  | DOI:10.1038/s41598-017-00739-y
A point mutation stabilises the RNA G4 in the 5′ UTR of TAOK2. In addition to the destabilising 
mutations, our bioinformatics analyses predicted several mutations in the G-rich regions of 5′ UTRs that can 
stabilise potential RNA G4 structures (Supplementary Table 3). One of these mutations, which has been reported 
in a patient with colon cancer, overlaps a predicted RNA G4 in the 5′ UTR of TAOK2. This gene encodes a protein 
kinase, which involves in cell signalling pathways32 and the induction of apoptosis33. The mutation is an adenine 
to guanine located next to two adjacent guanines in the first loop. The mutation adds a G-run to the existing four 
G-runs and based on RNAfold and QGRS-Mapper predictions, it stabilises the RNA G4 by changing the arrange-
ment of G-runs involved in the G4 structure formation and shortening one of the loops (Fig. 6A; Supplementary 
Table 4).
CD spectra of wild-type and G4-mutated TAOK2 oligos showed that they can fold into a parallel G4 confor-
mations in near physiological pH and potassium concentration (Fig. 6B), whereas in lithium-containing buffer, 
the G4 structure signature is much weaker (Supplementary Figure 1). CD melting curves of these oligos (Fig. 6C) 
showed that the Tm value of the G4-mutated TAOK2 oligo is 7 °C higher than that of the wild-type oligo (Table 1), 
which further supports the increased stability of the RNA G4.
Three different luciferase reporter constructs were generated (Fig. 6A) as described earlier for BCL2 and 
CXCL14, to evaluate the G4 stabilising effect of this mutation in vitro. Compared to the wild-type G4 construct, 
the G4-mutated construct showed 25% lower translation efficiency (P < 0.0001), whereas the G4-deleted con-
struct showed a significant increase in translation efficiency (P < 0.0001) (Fig. 6D). These results indicate that the 
mutated RNA G4 is more efficient in acting as a translational suppressor motif, which could be the consequence 
of its elevated thermodynamic stability.
Figure 5. Two adjacent mutations in the 5′ UTR of CXCL14 destabilise the RNA G4 and affect its regulatory 
function. (A) Schematic representation of three different mRNAs of firefly luciferase reporter constructs. Wild-
type construct contains full-length 5′ UTR of CXCL14. In the G4-mutated construct, two guanines are replaced 
by two adenines. To make the G4-deleted construct, 23 nucleotides that predicted to form the RNA G4 were 
deleted. Schematic drawing of wild-type and mutated G4s are proposed based on RNAfold and QGRS-mapper 
predictions and in vitro results. (B) CD spectra of CXCL14 wild-type and mutated RNA G4 oligos in KCl. (C) 
CD melting curves of CXCL14 wild-type and mutated RNA G4 oligos at 260 nm. (D) Relative in vitro translation 
efficiency of the wild-type, G4-mutated and G4-deleted constructs as judged by measuring firefly luciferase 
enzymatic activity. Data were analysed using one-way-ANOVA (n ≥ 3, error bars represent the SEM, asterisks 
(*) indicate significance calculated by the Tukey multiple comparisons test).
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Discussion
Cancer is considered as a multifactorial disease, where a combination of genetic and environmental factors con-
tributes to cancer development, rather than a single gene mutation3. Most studies carried out to date have focused 
on the sequencing and characterization of mutations in protein-coding regions of the genome. However, knowl-
edge regarding the effect of noncoding mutations in cancer development is very limited. Given that important 
regulatory elements, such as promoters and UTRs of mRNAs, are located in noncoding regions, it is likely that 
cancer driver mutations are found in these regions. Mutations in these regions can affect the structure and stabil-
ity of regulatory motifs, including G4 structures. A number of G4s have been characterised as regulatory motifs in 
the promoters of many genes including proto-oncogenes, such as c-KIT34 and KRAS35. In addition to the promot-
ers, there is evidence for regulatory functions of G4s in the 5′ UTR of several genes including BCL228 and NRAS21 
proto-oncogenes. Furthermore, a significant association between single nucleotide polymorphisms located in 
predicted G4 sequences and expression of the corresponding gene in individuals was previously demonstrated 
in a genome-wide study36. Here, for the first time, to the best of our knowledge, we demonstrate that noncoding 
mutations in cancer alter RNA G4s stability and affect their regulatory functions in the 5′ UTRs.
Using publically available whole-genome sequencing data, we found 217 mutations that overlap the potential 
G4-forming sequences in 5′ UTRs. To distinguish mutations that potentially alter G4 stability from inconse-
quential mutations, we evaluated the effects of the mutations on predicted G4 structures using RNAfold. This 
software considers the most important thermodynamic parameters, which contribute to RNA G4 stability26. To 
mimic the biological condition as much as possible, we examined the effect of each overlapping mutation in the 
context of the full-length 5′ UTR. We found 33 RNA G4 destabilising and 21 stabilising mutations and selected 
one stabilising mutation in the 5′ UTR of TAOK2, one destabilising mutation in the 5′ UTR of BCL2 and two 
adjacent destabilising mutations in the 5′ UTR of CXCL14 to validate experimentally. It is noteworthy that if the 
Figure 6. A point mutation in the 5′ UTR of TAOK2 stabilises the RNA G4 and affect its regulatory function. 
(A) Schematic representation of three different mRNAs of firefly luciferase reporter constructs. Wild-type 
construct contains full-length 5′ UTR of TAOK2. In the G4-mutated construct, an adenine is replaced by 
a guanine. To make the G4-deleted construct, 27 nucleotides that predicted to form the G4 were deleted. 
Schematic drawing of wild-type and mutated G4s are proposed based on RNAfold and QGRS-mapper 
predictions and in vitro results. (B) CD spectra of TAOK2 wild-type and mutated RNA G4 oligos in KCl. (C) 
CD melting curves of TAOK2 wild-type and mutated RNA G4 oligos at 260 nm. (D) Relative in vitro translation 
efficiency of the wild-type, G4-mutated and G4-deleted constructs as judged by measuring firefly luciferase 
enzymatic activity. Data were analysed using one-way-ANOVA (n ≥ 3, error bars represent the SEM, asterisks 
(*) indicate significance calculated by the Tukey multiple comparisons test).
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RNAfold was used initially to find the overlapping mutations instead of the Quadparser algorithm, we might have 
overlooked the stabilising mutations.
BCL2 is a human proto-oncogene and belongs to the Bcl-2-family of proteins. These proteins are responsible 
for the physiological regulation of apoptosis, which is essential for development and tissue homeostasis27. Many 
examples exist where the expression of BCL2 is elevated in human malignancies, particularly lymphomas. Several 
mechanisms contribute to the overexpression of BCL2, including chromosomal translocations and loss of endog-
enous microRNAs that repress BCL2 expression37. In addition, it has been demonstrated that cis-regulatory muta-
tions contribute to the dysregulation of the BCL2 expression38. Balasubramanian et al. characterised a very stable 
RNA G4 in the 5′ UTR of BCL2, which was found to negatively regulate translation of the gene in vitro28. Here, 
we report a mutation from a patient with malignant lymphoma that overlaps this RNA G4. Comparison between 
CD melting curves and Tm values of the wild-type and mutated BCL2 RNA G4 show that the mutation destabilises 
this RNA G4 (Fig. 3C; Table 1). In order to rule out the possibility that the G4 flanking sequence might interfere 
with its formation and stability, we included 20 adjacent nucleotides from each side and repeated the biophysical 
study using 62-mer wild-type and mutated oligos. As shown in Fig. 4A, the CD spectra of both 62-mer wild-type 
and mutated oligos have the characteristic peaks for parallel propeller G4 structure. In addition, we observed that 
the difference between Tm values of the 62-mer wild-type and mutated oligos are almost the same as the 22-mer 
oligos (Table 1) denoting that the flanking sequence of BCL2 RNA G4 does not interfere with this G4 structure 
and stability. Using in vitro luciferase reporter assays, we show that this mutation significantly elevates the trans-
lation efficiency (Fig. 3D). We verified this result by performing dual luciferase assay in MCF-7 cell line. We 
observed ~75% increase in the gene expression at the protein level for the BCL2 G4-mutant construct, whereas 
there is not a significant difference in the gene expression at the mRNA level between the BCL2 G4-mutant and 
wild-type constructs. Taken together, these results suggest the guanine to adenine point mutation in one of the 
G-tetrads of BCL2 RNA G4 does not completely disrupt the G4 structure, but significantly decreases its stability 
and affects its regulatory capability as a translational repressor in the 5′ UTR of the BCL2 proto-oncogene.
We also experimentally validated the effect of two adjacent guanine to adenine destabilising mutations in 
a patient with melanoma that overlap a predicted RNA G4 in the 5′ UTR of CXCL14. This gene belongs to the 
CXC subfamily of chemokines, which are involved in immunoregulatory and inflammatory processes. Tumor 
suppressing and promoting activities have been reported for CXCL14, depending on the type and the stage of can-
cer39, 40. We showed that the mutations decrease the Tm value of the mutated RNA G4 oligo (Table 1) and increase 
the translation efficiency of the gene (Fig. 5D) probably because they rearrange the G4 structure by lengthening 
one of the loops and making the G4 structure less stable.
Contrary to mutations that destabilise G4 structures, some mutations in G-rich sequences can stabi-
lise G4 structures and in turn affect their physiological function. Among 21 stabilising mutations listed in the 
Supplementary Table 3, we experimentally validated the effect of a mutation on a predicted G4 in the 5′ UTR of 
TAOK2. This gene is one of the TAO (thousand-and-one amino acids) protein kinases that involves in several 
different cellular processes including cell-signalling pathways32, 41, 42. TOAK2 has been suggested to be involved 
in the induction of apoptosis33. Here, we demonstrated that the predicted G4 sequence in the 5′ UTR of TAOK2 
folds into a parallel quadruplex in vitro (Fig. 6B) and a mutation in a patient with colon cancer increases the Tm 
value of the mutated TAOK2 RNA G4 oligo (Table 1) and decreases the translation efficiency compared to the 
wild-type (Fig. 6D). The elevated stability in the mutated TAOK2 RNA G4 might be attributed to the reorganisa-
tion of G-runs caused by the mutation. There are two successive guanines in the first loop of TAOK2 RNA G4. The 
adenine to guanine mutation next to these guanines together form a new G-run that shifts the last G-run outside 
the RNA G4. Therefore, the first loop is shortened and the RNA G4 becomes more stable.
The results presented in this paper are based on bioinformatics analyses and in vitro experiments that show 
somatic mutations in cancer patients can alter RNA G4 structure stability in the 5′ UTR of mRNAs and affect its 
regulatory function. This study provides evidence for the concept that these mutations might contribute to cancer 
development. Recently, Balasubramanian and colleagues developed a method for high-throughput sequencing 
of DNA G4s and identified more than 700,000 unique G4 structures in the genome, which is more than twice the 
number of G4s predicted by computational methods43. This dataset represents a good starting point for a deeper 
analysis of the effect of mutations on G4 structure and function. Analysing larger datasets might obviate the lack 
of recurrency among the G4 stabilising or destabilising mutations observed in this study. Finally, considering 
that G4 binding ligands can stabilise G4 structures, it will be important to investigate whether they can restore 
the stability of a destabilised G4. Such ligands may include small organic molecules or alternately protein ligands 
such as antibody fragments which can be generated by in vitro selection technology23, 44. Further understanding 
of the relationship of the pathogenicity of variants within G4 structures will improve the diagnostic potential of 
genome sequencing for both somatic and germline mutations and may form a basis for new therapeutic targets.
Material and Methods
The sequences of all of the oligonucleotides used in the biophysical studies, primers and 5′ UTRs are provided in 
Supplementary Table 1.
Bioinformatics. Somatic mutation data from whole cancer genomic sequences were obtained from three 
publicly available data sources: TCGA, ICGC and Alexandrov et al.25. The single base substitution data from the 
ICGC were obtained from the ICGC data portal (release 16) and the FTP site provided by Alexandrov et al. These 
mutations were used directly for the analysis. For samples obtained from TCGA, mutations were called from 
BAM files obtained from CGHub using Strelka with default parameters45. The genomic coordinates of somatic 
variants are reports using NCBI build 37, aka hg19.
Quadparser algorithm13 was used to identify potential G4-forming sequences in the NCBI build 37 version of 
the human genome sequence. UCSC Table Browser46 was used to find the overlaps between identified mutations 
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and potential G4-forming sequences in the 5′ UTR regions. The effect of a mutation on the thermodynamic sta-
bility of an RNA G4 was evaluated using RNAfold and RNALfold26 version 2.1.9 in the context of the full-length 
5′ UTR while GU base paring was not allowed. In addition to RNAfold, the QGRS-Mapper14 online tool was used 
to investigate the effect of mutations on the RNA G4-forming sequences in the 5′ UTR of BCL2, CXCL14 and 
TAOK2.
Circular dichroism spectroscopy. Circular dichroism spectra were recorded as previously described47. 
Briefly, RNA oligos were annealed by heating at 90 °C for 10 minutes and slowly cooling down to room tempera-
ture. CD spectra were recorded at 25 °C on an Aviv 215S circular dichroism spectrometer equipped with a Peltier 
temperature controller. RNA G4 samples of the desired sequence were prepared at 5 µM in the G4 folding buffer 
(100 mM KCl, 20 mM Tris HCl pH 7.5). KCl was replaced by LiCl in the control samples. Four scans were accu-
mulated over the wavelength range 220–320 nm in a 0.1 cm path length cell at the standard sensitivity, data pitch 
0.1 nm, continuous scanning mode, scanning speed 100 nm min−1, response 4 sec, and bandwidth 1 nm. Buffers 
alone were scanned and these spectra subtracted from the average scans for each sample. Tm analysis was recorded 
by CD at 260 nm and heated at 1 °C min−1 over the temperature range 25–95 °C. CD and melt curve spectra were 
collected in units of millidegrees, normalized to the total species concentrations and expressed as molar ellipticity 
units (deg × cm2 dmol−1). Each CD spectrum was smoothed by averaging ten neighbour points using Prism 6. 
Sigmoidal dose-response curves (variable slope) were fitted to the melt curve data using Prism 6.
Construction of plasmids. Overlap extension PCR was used to clone either T7 or CMV promoter upstream 
of multiple restriction sites of pGL3 basic plasmid (Promega). The sequences of the 5′ UTRs of BCL2, CXCL14 
and TAOK2 were obtained from the UCSC Genome Browser48 based on the NCBI build 37 version of the human 
genome sequence. The synthetically synthesised full-length 5′ UTRs of each candidate was purchased from 
GenScript and inserted in the KpnI and HindIII restriction sites of T7 or CMV pGL3 plasmid. These constructs 
are considered as wild-types. G4-mutated and G4-deleted constructs were created based on the wild-type con-
structs for each 5′ UTR. The NEBaseChangerTM online tool provided by New England BioLabs was used to design 
primers for making desired point mutations in the G4-forming sequences and also deleting the entire G4-forming 
sequences from the 5′ UTRs.
In vitro transcription. A gene fragment containing T7 promoter and the full-length 5′ UTR attached to the 
firefly luciferase gene was provided from each of the wild-types, G4-mutated and G4-deleted constructs by PCR 
amplification. The size of each fragment was examined on a 1% agarose gel followed by gel purification. An addi-
tional step of PCR clean up was performed and RNase inhibitor (Ambion) at a final concentration of 1 U/μL was 
added to each sample. The PCR products were used as templates to produce 5′-capped transcripts in vitro using 
mMESSAGE mMACHINE T7 kit (Ambion). Transcripts were DNase treated and purified using the RNeasy Mini 
Kit (QIAGEN). The size and integrity of the transcripts were confirmed on a 1% agarose gel. The concentration of 
each set of transcripts was determined by NanoDrop.
In vitro translation and luciferase assay. Nuclease-treated rabbit reticulocyte lysate (Promega) was used 
to perform the cell-free translation. 150 ng/μL (final concentration) of the in vitro transcribed 5′-capped mRNA 
containing the full-length 5′ UTR attached to the firefly luciferase coding sequence was translated according to 
the manufacturer’s protocol. In order to measure the firefly luciferase activity, 5 μL of the translation reaction was 
added to 75 μL of luciferase assay reagent (Promega) at room temperature. The reaction was quickly mixed and 
luminescence was measured using CLARIO star microplate reader (BMG LABTECH).
Dual luciferase assay and RT-PCR. MCF-7 cells were seeded in 12-well plates (Corning) and incubated 
until they reached to 70–80% confluency. The cells were co-transfected with pRL-TK (Promega) normalizing 
vector, which expresses renilla, and the CMV pGL3 plasmids constructs, which prepared as described earlier 
and express firefly, with the ratio of 1 to 7 using Lipofectamine 3000 (Thermo Fisher Scientific) according to 
the manufacturer’s protocol. When cells reached to 90–95% confluency, renilla and firefly luciferase activities 
were measured using Dual-Luciferase Reporter Assay System (Promega) following the manufacturer’s protocol 
in the CLARIO star microplate reader (BMG LABTECH). Total RNA was extracted from the remaining cells 
using RNeasy mini kit (QIAGEN). 200 ng of each total RNA sample was reverse-transcribed using SuperScript 
III First-Strand Synthesis System (Thermo Fisher Scientific). The cDNA from each sample was used to perform 
RT-qPCR using LightCycler 480 SYBR Green I Master reagents (Roche) and a LightCycler 480 SYBR device 
(Roche). Primer sets are listed in the Supplementary Table 1. The relative mRNA expression level was calcu-
lated using the following mathematical model49: Ratio = (E target)ΔCPtarget(control-sample)/(E reference)ΔCPreference(control-sample) 
where firefly and renilla were considered as the target and reference genes, respectively. GAPDH expression in 
each sample was considered as the control.
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